# US 6,844,000 B2 · Use of Parapox B2L protein to treat cancer and modify immune responses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,844,000 B2
- Document ID: US6844000B2
- Status: Granted
- Kind: B2
- Application number: 10/313,332
- Filed: 2002-12-06
- Published: 2003-06-12
- Granted: 2005-01-18
- Earliest claimed: 2001-12-07
- Assignees: Bayer Pharmaceuticals Corporation
- Inventors: Delanie Cassell; Jeffrey S. Tepper; Isa Samuels; Nathalie Dubois-Stringfellow
- Web page: https://patentgrep.com/patent/US6844000B2

## CPC

- C07K 14/005: from viruses
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/55516: {Proteins; Peptides}
- C07K 2319/21: containing a His-tag
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C12N 2710/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/24233: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A purified Parapoxvirus ovis envelope protein termed “B2L” can be used as a monotherapeutic agent. B2L protein also can be used in screening methods to identify potential therapeutic agents for modulating a subject's immune response to the B2L protein.

## Claims

### Claim 1

A method of treating a patient having a cell proliferative disorder, comprising the step of:
administering to the patient an effective amount of a purified and isolated B2L viral envelope protein of a Parapox virus, whereby symptoms of the patient's cell proliferative disorder are ameliorated.

### Claim 2 (depends on 1)

The method of claim 1 wherein the B2L protein is administered systemically.

### Claim 3 (depends on 1)

The method of claim 1 wherein the B2L protein is injected into a tumor or dysplastic lesion.

### Claim 4

A method of enhancing an immune response to endogenous antigens associated with a cell proliferative disorder, comprising the step of:
administering to a subject in need thereof an effective amount of a purified and isolated B2L viral envelope protein of a Parapox virus, whereby the B2L viral envelope protein enhances the immune response to the endogenous antigens.